Our prime targets

Aspergillus and Candida

By focusing the efforts of BlueTile on Aspergillus fumigatus and Candida, we are targeting the "Critical Priority" group—the highest tier of medical urgency defined by the WHO.

Our R&D strategy is directly aligned with the World Health Organization (WHO) Fungal Priority Pathogens List (2022). This landmark report identifies 19 fungi (see list below) that pose the greatest threat to public health, categorizing them based on their unmet medical need and the urgent requirement for novel therapeutic solutions.

Why We Focus on These Pathogens:

Global Health Urgency: Aspergillus fumigatus and several Candida species (such as C. auris and C. albicans) are responsible for the highest rates of morbidity and mortality in hospital settings worldwide.

A Growing Threat in the West: these pathogens are a major and growing crisis within European and North American healthcare systems, where aging populations and increasing ICU admissions have led to a surge in invasive infections.

The Resistance Crisis: current treatments in the EU and USA are failing due to rising antimicrobial resistance (AMR). Our technology provides a critical alternative where traditional generics are no longer effective.